Brief: Atossa Completes Enrollment Of Pharmacokinetic Run-In Cohort In Phase 2 Evangeline Clinical Trial Evaluating (Z)-Endoxifen As
12/06/2023 14:55
June 12 (Reuters) - Atossa Therapeutics Inc ATOS.O :
* ATOSSA COMPLETES ENROLLMENT OF PHARMACOKINETIC RUN-IN
COHORT IN
PHASE 2 EVANGELINE CLINICAL TRIAL EVALUATING (Z)-ENDOXIFEN AS A
NEOADJUVANT TREATMENT FOR ER+ / HER2- BREAST CANCER
* ATOSSA THERAPEUTICS - TO FULLY ENROLL EVANGELINE PK RUN-IN
COHORT AND LOOK FORWARD TO SEEING DATA IN Q3 OF THIS YEAR
Source text for Eikon: ID:nGNX6KQPby
Further company coverage: ATOS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atossa Therapeutics
See all newsAtossa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline
Brief: Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary